TWI577693B - 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 - Google Patents

聚（ａｄｐ-核糖）聚合酶之三環抑制劑 Download PDF

Info

Publication number
TWI577693B
TWI577693B TW101119653A TW101119653A TWI577693B TW I577693 B TWI577693 B TW I577693B TW 101119653 A TW101119653 A TW 101119653A TW 101119653 A TW101119653 A TW 101119653A TW I577693 B TWI577693 B TW I577693B
Authority
TW
Taiwan
Prior art keywords
compound
substituted
pharmaceutically acceptable
unsubstituted
acceptable salt
Prior art date
Application number
TW101119653A
Other languages
English (en)
Chinese (zh)
Other versions
TW201311713A (zh
Inventor
沈旺
杰克 滿
張愛民
鄭曉玲
Original Assignee
江蘇康緣藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇康緣藥業股份有限公司 filed Critical 江蘇康緣藥業股份有限公司
Publication of TW201311713A publication Critical patent/TW201311713A/zh
Application granted granted Critical
Publication of TWI577693B publication Critical patent/TWI577693B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW101119653A 2011-05-31 2012-05-31 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 TWI577693B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161491851P 2011-05-31 2011-05-31

Publications (2)

Publication Number Publication Date
TW201311713A TW201311713A (zh) 2013-03-16
TWI577693B true TWI577693B (zh) 2017-04-11

Family

ID=47259874

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101119653A TWI577693B (zh) 2011-05-31 2012-05-31 聚（ａｄｐ-核糖）聚合酶之三環抑制劑

Country Status (8)

Country Link
US (5) US20140221314A1 (enExample)
EP (2) EP3925962A1 (enExample)
JP (1) JP5960253B2 (enExample)
CN (1) CN103717609B (enExample)
CA (1) CA2875025C (enExample)
ES (1) ES2871052T3 (enExample)
TW (1) TWI577693B (enExample)
WO (1) WO2012166983A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
CN111936143A (zh) * 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
CN119390683A (zh) 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CN114276301B (zh) * 2020-09-27 2025-04-01 江西科睿药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183325A1 (en) * 2000-10-30 2002-12-05 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU9578901A (en) 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
US7402580B2 (en) 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1791827A1 (en) 2004-08-26 2007-06-06 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2009544611A (ja) * 2006-07-20 2009-12-17 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
PT2698062E (pt) 2006-12-28 2015-10-19 Abbvie Inc Inibidores da poli (adp-ribose) polimerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
AU2008313467B2 (en) * 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
WO2009063244A1 (en) 2007-11-15 2009-05-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Pyridazinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2300013B2 (en) * 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JP5721709B2 (ja) 2009-07-02 2015-05-20 ニューゲン セラピューティクス， インコーポレイテッド リンを含むキナゾリン化合物および使用方法
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183325A1 (en) * 2000-10-30 2002-12-05 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives

Also Published As

Publication number Publication date
WO2012166983A1 (en) 2012-12-06
US12612425B2 (en) 2026-04-28
EP3925962A1 (en) 2021-12-22
JP2014516989A (ja) 2014-07-17
EP2714703A1 (en) 2014-04-09
US20170057984A1 (en) 2017-03-02
US11248013B2 (en) 2022-02-15
JP5960253B2 (ja) 2016-08-02
US20180094010A1 (en) 2018-04-05
CA2875025A1 (en) 2012-12-06
CN103717609B (zh) 2016-05-11
US20200299315A1 (en) 2020-09-24
CA2875025C (en) 2021-08-03
ES2871052T3 (es) 2021-10-28
EP2714703A4 (en) 2014-12-31
CN103717609A (zh) 2014-04-09
EP2714703B1 (en) 2021-03-10
US20230027257A1 (en) 2023-01-26
TW201311713A (zh) 2013-03-16
US20140221314A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
US12612425B2 (en) Tricyclic inhibitors of poly(ADP-ribose)polymerase
AU2009203598B2 (en) Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide
JP5856151B2 (ja) Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
JP5836367B2 (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
TWI528961B (zh) 作為聚（ａｄｐ-核糖）聚合酶（ｐａｒｐ）抑制劑之經醯胺取代之吲唑
UA123813C2 (uk) Заміщені індазоли, способи їх одержання, фармацевтичні препарати, які їх містять, та їх застосування для одержання лікарських засобів
UA123785C2 (uk) Сполуки піролотриазину як інгібітори tam
WO2008084261A1 (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP2013529643A (ja) Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
JP2014528419A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
UA112096C2 (uk) Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP2013526540A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
TW201249829A (en) Bipyridylaminopyridines as Syk inhibitors
JP2007504096A (ja) 急性及び／又は慢性神経障害の治療のためのｍＧｌｕＲ２アンタゴニストとＡＣｈＥインヒビターの併用
JP2025535496A (ja) 化合物及びその使用
TW201038546A (en) Modulators of S1P and methods of making and using
JP2020523361A (ja) ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤、調製方法および使用
US20170121325A1 (en) Fused imidazole derivatives as ido/tdo inhibitors